The AMD Experts
We’re on a mission to eliminate blindness caused by age-related macular degeneration (AMD). Our vision is bold but well within reach.
MacuLogix is the only company to equip eye care professionals with the technology, tools, and education needed to identify and manage AMD patients early, before irreversible vision loss has occurred. We can help you deliver better patient care with the scientifically-validated, FDA 510(k)-cleared AdaptDx Pro™.
Help us save the eyesight of millions by making early functional testing for AMD a routine part of eye care for your aging patients.
The MacuLogix team is committed to empowering primary eye care professionals with the technology and tools needed to create AMD Centers of Excellence®.
Bill McPhee, the President and CEO of MacuLogix, shares his personal story of why he joined the company and adopted its vision of eliminating blindness caused by AMD.
By being able to test more patients, we’ll ultimately uncover more macular degeneration. That’s good for patients. And I think we all need to realize is that what’s good for our patients winds up being good for our practices.
Latest News & Upcoming EventsView More
If you want to help identify AMD patients sooner so that management can begin before substantial vision loss occurs, a new product from Maculogix aims to help.
MacuLogix, Inc. announces the next generation of dark adaptation functional testing with the introduction of the AdaptDx Pro guided by Theia.
How at-home genetic testing has affected AMD patient encounters with eye care practitioners. By Dr. Damon Dierker, OD, FAAO and Dr. Scott Schachter, OD.
Put Our Expertise to Work
Testing with AdaptDx Pro
AdaptDx Pro identifies impaired dark adaptation—the earliest warning sign of AMD.
Each AdaptDx Pro purchase is supported by our AMD Excellence Program™ to help you achieve your patient care and practice revenue goals.